-+ 0.00%
-+ 0.00%
-+ 0.00%

Raymond James Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $22

Benzinga·09/09/2026 17:49:54
语音播报
Raymond James analyst Sean McCutcheon maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and lowers the price target from $24 to $22.